apl-1202

Small moleculeexperimental

Clinical trial activity

8 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
5
Phase 3
2
Phase 4
0

Earliest trial started May 13, 2014 (NCT04498702)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06435039Phase 1Jun 26, 2024Jiangsu Asieris Pharmaceutical Technology Co., Ltd., Syneos Health
NCT06034015Phase 1Sep 9, 2023Jiangsu Asieris Pharmaceutical Technology Co., Ltd.
NCT04736394Phase 3Oct 1, 2021Jiangsu Asieris Pharmaceutical Technology Co., Ltd.
NCT04813107Phase 1/Phase 2 (Phase 2)Sep 1, 2021Jiangsu Asieris Pharmaceutical Technology Co., Ltd.
NCT04601766Phase 1Oct 21, 2020Jiangsu Asieris Pharmaceutical Technology Co., Ltd.
NCT03672240Phase 1/Phase 2 (Phase 2)Oct 31, 2018Accelovance, Jiangsu Asieris Pharmaceutical Technology Co., Ltd.
NCT04490993Phase 3Mar 30, 2017Chinese Academy of Medical Sciences, Fudan University
NCT04498702Phase 2May 13, 2014Fudan University
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Jiangsu Asieris Pharmaceutical Technology Co., Ltd.For profit6532018
Fudan UniversityAcademic/Hospital2022014
AccelovanceFor profit1012018
Chinese Academy of Medical SciencesAcademic/Hospital1012017
Syneos HealthFor profit1112024
5 organizations
Page 1 / 1